OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
As disclosed in the October13, 2017 press release filed as an exhibit to the Company’s Current Report on Form 8-K, the United States District Court for the District of Delaware issued a ruling in favor of Orexigen in the paragraph IV litigation against Actavis Laboratories FL, Inc. (Actavis) for all three patents for Contrave that were the subject of the litigation. The Company’s successful defense of its intellectual property led to the favorable ruling, which provides exclusivity for Contrave until 2030. The full opinion of the court may be found on the website for the United States District Court for the District of Delaware at http://www.ded.uscourts.gov/judges-info/opinions.
The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished to Item 2.02 and shall not be deemed “filed” for purposes of Section18 of the Exchange Act, or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report.
** *
Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements that are subject to a number of risks and uncertainties, including statements relating to the Company’s third quarter 2017 financial estimates, its ability to enter into various strategic transactions, potential 2018 sales and other matters. Actual results may differ materially from those set forth in this Current Report on Form8-K. These and other risks and uncertainties are detailed in the risk factors included in the Company’s Quarterly Report on Form10-Q filed with the Securities and Exchange Commission on August9, 2017, as amended. Except as required by law, the Company undertakes no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Item 2.02Financial Statements and Exhibits
(d)Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Slide Presentation, dated October 16, 2017 |
Orexigen Therapeutics, Inc. ExhibitEX-99.1 2 d476732dex991.htm EX-99.1 EX-99.1 BIO Investor Forum Michael Narachi Chief Executive Officer October 17,…To view the full exhibit click here
About OREXIGEN THERAPEUTICS, INC. (NASDAQ:OREX)
Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.
